Cargando…

Determinants of response to CDK4/6 inhibitors in the real-world setting

Despite widespread use and a known mechanism of action for CDK4/6 inhibitors in combination with endocrine therapy, features of disease evolution and determinants of therapeutic response in the real-world setting remain unclear. Here, a cohort of patients treated with standard-of-care combination re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witkiewicz, Agnieszka K., Schultz, Emily, Wang, Jianxin, Hamilton, Deanna, Levine, Ellis, O’Connor, Tracey, Knudsen, Erik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499925/ https://www.ncbi.nlm.nih.gov/pubmed/37704753 http://dx.doi.org/10.1038/s41698-023-00438-0

Ejemplares similares

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016)

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
por: Franco, Jorge, et al.
Publicado: (2014)

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
por: Knudsen, Erik S., et al.
Publicado: (2017)

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2014)

Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2021)

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
por: Franco, Jorge, et al.
Publicado: (2020)

Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer
por: Kumarasamy, Vishnu, et al.
Publicado: (2019)

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
por: Knudsen, Erik S., et al.
Publicado: (2022)

Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience
por: Alaklabi, Sabah, et al.
Publicado: (2022)

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015)

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
por: Witkiewicz, Agnieszka K, et al.
Publicado: (2014)

Cell cycle plasticity driven by MTOR signaling: Integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
por: Knudsen, Erik S., et al.
Publicado: (2019)

Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
por: Miron, Andreea-Iuliana, et al.
Publicado: (2023)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

Determinants of severe QT(c) prolongation in a real-world gerontopsychiatric setting
por: Schulze Westhoff, Martin, et al.
Publicado: (2023)

Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential
por: Knudsen, Erik S., et al.
Publicado: (2016)

Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations
por: Grant, Adam D., et al.
Publicado: (2019)

Symptom study app provides real-world data on COVID-19 vaccines
por: Drury, Ruth E, et al.
Publicado: (2021)

Determination of Postprandial Glycemic Responses by Continuous Glucose Monitoring in a Real-World Setting
por: Röhling, Martin, et al.
Publicado: (2019)

Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data
por: Martin, James M, et al.
Publicado: (2022)

Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
por: Low, Jia Li, et al.
Publicado: (2022)

Hidden altruism in a real-world setting
por: Raihani, N. J.
Publicado: (2014)

Increased CDK1 activity determines the timing of kinetochore-microtubule attachments in meiosis I
por: Davydenko, Olga, et al.
Publicado: (2013)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

Assessment of Infectious Diseases Risks From Dental Aerosols in Real-World Settings
por: Choudhary, Shruti, et al.
Publicado: (2022)

SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey
por: Prager, G., et al.
Publicado: (2021)

Validation of an LC-MS/MS Method for the Determination of Abscisic Acid Concentration in a Real-World Setting
por: Schiano, Elisabetta, et al.
Publicado: (2023)

Impact of novel insertable cardiac monitoring system on real-world cardiac device clinic workflow
por: Rosemas, S C, et al.
Publicado: (2023)

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
por: Engler, Tobias, et al.
Publicado: (2022)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

Efficacy of Generic Atorvastatin in a Real-World Setting
por: Manasirisuk, Panisa, et al.
Publicado: (2021)

Performance Characteristics of Breezhaler(®) and Aerolizer(®) in the Real-World Setting
por: Molimard, Mathieu, et al.
Publicado: (2021)

TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
por: Bazhenova, Lyudmila, et al.
Publicado: (2021)

Weighty Matters: A Real-World Comparison of the Handtevy and Broselow Methods of Prehospital Weight Estimation
por: Knudsen-Robbins, Chloe, et al.
Publicado: (2022)

Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting—initial results
por: Moisander, Mikko, et al.
Publicado: (2021)

Pan-cancer molecular analysis of the RB tumor suppressor pathway
por: Knudsen, Erik S., et al.
Publicado: (2020)

A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
por: Tang, Hui, et al.
Publicado: (2023)

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: West, Malinda T, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1rpnp94r6i6iv1l13idf28un8a